TP53 and neoplasm: There are currently 14 clinical trials ongoing in 8 tumour types to assess whether CDK4/6 inhibition can improve response to anti‐cancer immunotherapy (Wagner & Gil, 2020), therefore it will also be important to assess whether p53 status correlates with response in these situations.